NDA 022571 · Merz Pharms
Cuvposa
Glycopyrrolate · Oral
OrphanLast checked: Nov 19, 2026Latest source record: Feb 23, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Jul 28, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
230
60 Phase 3, 12 recruiting
FAERS reports
5,640
4,741 serious, 679 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 19, 2024.
CUVPOSA is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). CUVPOSA is an anticholinergic indicated to reduce chronic severe drooling in patients aged 3-16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). ( 1 )
Mechanism: Glycopyrrolate is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including salivary glands. Glycopyrrolate indirectly reduces the rate of salivation by preventing the stimulation of these receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 28, 2010 Original approval · Type 3 - New Dosage Form OrphanSummary ReviewLabelReview
1 products under this application
- CUVPOSA · GLYCOPYRROLATE 1MG/5ML · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Glycopyrrolate" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
Novartis PharmaceuticalsNovartis (NVS)
NCT01985334 · 4,389 participants · Start Feb 14, 2014 · Primary completion Apr 29, 2016
Drug: Glycopyrronium; SABA and 5 more · For: COPD
Sites: Amstetten, Austria; Feldkirch, Austria; Hallein, Austria · 542 sites in all
- Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT01911364 · 3,686 participants · Start Jan 2014 · Primary completion Mar 2016
Drug: BDP/FF/GB; Tiotropium and 1 more · For: Chronic Obstructive Pulmonary Disease
Sites: Hessen, Germany; Szeged, Hungary; Perugia, Italy
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPDPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT04320342 · 3,406 participants · Start Apr 27, 2022 · Primary completion Jan 12, 2026
Drug: Beclomethasone Dipropionate; Glycopyrronium Bromide and 1 more · For: COPD; COPD Exacerbation
Sites: Birmingham, Alabama; Dothan, Alabama; Foley, Alabama · 436 sites in all
- Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) ExacerbationsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01120691 · 2,224 participants · Start Apr 2010 · Primary completion Jul 2012
Drug: QVA149; NVA237 and 2 more · For: Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Fairhope, Alabama; Florence, Alabama · 342 sites in all
- A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01202188 · 2,144 participants · Start Sep 2010 · Primary completion Feb 2012
Drug: indacaterol and glycopyrronium (QVA149); glycopyrronium (NVA237) and 3 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Fullerton, California; Riverside, California; St. Petersburg, Florida · 166 sites in all
- Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPDPivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02343458 · 1,756 participants · Start Mar 30, 2015 · Primary completion Aug 31, 2017
Drug: GFF MDI (PT003); FF MDI (PT005) and 2 more · For: Chronic Obstructive Pulmonary Disease
Sites: Andalusia, Alabama; Birmingham, Alabama; Foley, Alabama · 166 sites in all
- Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT01854658 · 1,615 participants · Start Jul 2013 · Primary completion Mar 2015
Drug: GFF MDI (PT003); GP MDI (PT001) and 2 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Birmingham, Alabama; Florence, Alabama; Jasper, Alabama · 113 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,058
- asthma853
- wheezing719
- cough670
- pneumonia585
- drug ineffective448
- off label use387
- fatigue376
- malaise365
- chronic obstructive pulmonary disease361
- productive cough350
- chest discomfort337
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 14 |
| 2006 | 16 |
| 2007 | 30 |
| 2008 | 29 |
| 2009 | 46 |
| 2010 | 62 |
| 2011 | 74 |
| 2012 | 88 |
| 2013 | 71 |
| 2014 | 128 |
| 2015 | 148 |
| 2016 | 230 |
| 2017 | 434 |
| 2018 | 300 |
| 2019 | 325 |
| 2020 | 289 |
| 2021 | 462 |
| 2022 | 632 |
| 2023 | 573 |
| 2024 | 611 |
| 2025 | 672 |
| 2026 | 393 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cuvposa (Glycopyrrolate)
2024 spending
$111K
Beneficiaries
62
246 claims
Per beneficiary
$1,796
$0.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,457,799 |
| 2021 | $1,483,413 |
| 2022 | $640,605 |
| 2023 | $266,778 |
| 2024 | $111,332 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials.
Fornaro M, Caiazza C, Solini N, et al. · Mol Psychiatry 2023 · Systematic Review, Network Meta-Analysis
- Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
Ferguson GT, Rabe KF, Martinez FJ, et al. · Lancet Respir Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
Martinez FJ, Rabe KF, Ferguson GT, et al. · Am J Respir Crit Care Med 2021 · Multicenter Study, Randomized Controlled Trial
- Glycopyrrolate in children.
Warran P, Radford P, Manford ML · Br J Anaesth 1981 · Clinical Trial, Comparative Study
- Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).
Singh D, Martinez FJ, Hurst JR, et al. · Am J Respir Crit Care Med 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Merz Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.